Submitted: 06 Jan 2018
Accepted: 31 Aug 2018
ePublished: 25 Sep 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2018;10(3): 118-128.
doi: 10.15171/jcvtr.2018.20
PMID: 30386531
PMCID: PMC6203864
  Abstract View: 966
  PDF Download: 606

Review Article

A systematic review on the cardiovascular pharmacology of Emblica officinalis Gaertn.

Fataneh Hashem-Dabaghian 1,2, Mojtaba Ziaee 3 ORCID logo, Samad Ghaffari 3, Farzaneh Nabati 4, Saeed Kianbakht 4 *

1 Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran
2 School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.
3 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran


Introduction: The Emblica officinalis (EO) fruit has traditionally been considered as a cardioactive medication and has demonstrated remarkable cardiovascular effects in the pharmacological literature. The present study systematically reviews EO’s potential for prevention and therapy of cardiovascular diseases (CVD).

Methods: PubMed, ScienceDirect, Scopus, Proquest, Ebsco, Google, Google Scholar, Ovid, and Cochrane databases were searched from 1966 to 2017 for the English and non-English literature using the terms including the cognates of EO including amla, Emblic myrobalan, Emblica officinalis, Emblica pectinata, Indian gooseberry, and Phyllanthus emblica together with antioxidant, arrhythmia, cardioprotective, cardiotoxicity, heart disease, heart failure, hyperlipidemia, hypertension, myocardial dysfunction, and oxidative stress. The inclusion criteria were in vitro, animal, and clinical cardiovascular pharmacological studies conducted on EO and full-text accessibility. The exclusion criterion was studies in which a combination of EO and at least one other plant was investigated. The reference lists of the retrieved articles were also searched manually for additional eligible articles. The methodological quality of clinical trials was assessed by the Jadad scale, and animal studies were evaluated by the ARRIVE checklist.

Results: Nineteen articles concerning the cardiovascular pharmacological effects of EO were included in this review. The plant has shown antiatherogenic, anticoagulant, hypolipidemic, antihypertensive, antioxidant, antiplatelet, and vasodilatory effects as well as lipid deposition inhibitory properties. Moreover, it prevents from doxorubicin and isoproterenol cardiotoxicity and myocardial ischemia/reperfusion injury, and improves vascular endothelial function in animal studies. Some high-quality clinical studies report the vasodilatory and myocardial antioxidant properties as well as anti-platelet aggregation effects of this plant.

Conclusion: EO influences various cardiovascular risk-factors. However, there is not sufficient evidence to confirm the plant efficacy in preventing and treating CVD. 

Keywords: Emblica officinalis, Cardiovascular Disease, Pharmacology, Phyllanthus emblica, Amla
Please cite this article as: Hashem-Dabaghian F, Ziaee M, Ghaffari S, Nabati F, Kianbakht S. A systematic review on the cardiovascular pharmacology of Emblica officinalis Gaertn. J Cardiovasc Thorac Res 2018;10(3):118-128. doi: 10.15171/jcvtr.2018.20.
First Name
Last Name
Email Address
Security code

Abstract View: 966

Your browser does not support the canvas element.

PDF Download: 606

Your browser does not support the canvas element.